Abstract
Predicting hospital readmission in cancer patients-particularly those with metastatic disease-remains a significant clinical challenge. While metastasis is known to affect prognosis, its role in shaping the relationship between standard clinical features (e.g., lab tests) and readmission risk remains poorly understood. In this study, we leverage the MIMIC-IV database to stratify patients by metastatic burden, defined by the number of metastatic sites, and analyze survival dynamics using a two-step neural-symbolic distillation framework. First, assuming the proportional hazards structure, we train a neural network to learn both the baseline hazard h0(t) and the log-partial hazard f (x), capturing complex, noisy survival patterns. We then distill the learned model into interpretable symbolic functions using Kolmogorov-Arnold Networks (KANs). For h0(t), we observe metastasis-specific linear or quadratic trends, with significantly steeper early-time hazards in patients with three or more metastatic sites-highlighting the need for enhanced post-discharge monitoring. To simplify the symbolization of f (x), we introduce a prestructuring step using B -spline expansions with both univariate and interaction terms. This reduces symbolic complexity and reveals that interaction effects dominate, with larger coefficients than univariate terms in most subgroups. The resulting symbolic expressions for f (x) vary substantially across metastasis strata, indicating that the influence of lab-derived features on readmission is metastasis-dependent. Our framework offers interpretable, metastasis-stratified survival models and provides a foundation for deeper exploration of lab-metastasis interactions in personalized cancer care.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
MIMIC IV database https://physionet.org/content/mimiciv/3.1/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
